| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)
|
Hazama, Shoichi
|
|
2016
|
15 |
4 |
p. 329-336
|
artikel
|
| 2 |
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma
|
Bowles, Daniel W.
|
|
2016
|
15 |
4 |
p. 337-344.e2
|
artikel
|
| 3 |
Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II Trial
|
Marchetti, Paolo
|
|
2016
|
15 |
4 |
p. 377-380
|
artikel
|
| 4 |
Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06)
|
Matter-Walstra, Klazien
|
|
2016
|
15 |
4 |
p. 314-320.e2
|
artikel
|
| 5 |
Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study
|
Cabart, Mathilde
|
|
2016
|
15 |
4 |
p. e165-e174
|
artikel
|
| 6 |
Colorectal Cancer Statistics From the Veterans Affairs Central Cancer Registry
|
Zullig, Leah L.
|
|
2016
|
15 |
4 |
p. e199-e204
|
artikel
|
| 7 |
Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2–Related Mechanism
|
Kim, Stefano
|
|
2016
|
15 |
4 |
p. e229-e234
|
artikel
|
| 8 |
Editorial Board
|
|
|
2016
|
15 |
4 |
p. A1
|
artikel
|
| 9 |
Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy
|
Loree, Jonathan M.
|
|
2016
|
15 |
4 |
p. 352-359.e1
|
artikel
|
| 10 |
Identifying High-Risk Stage II Colon Cancer Patients: A Three-MicroRNA-Based Score as a Prognostic Biomarker
|
Caritg, Oriol
|
|
2016
|
15 |
4 |
p. e175-e182
|
artikel
|
| 11 |
Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Pathologic Response to Preoperative Chemoradiotherapy and Prognosis in Patients With Locally Advanced Rectal Cancer
|
Koo, Phillip J.
|
|
2016
|
15 |
4 |
p. e213-e219
|
artikel
|
| 12 |
Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population
|
Shabihkhani, Maryam
|
|
2016
|
15 |
4 |
p. e221-e227
|
artikel
|
| 13 |
Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With a History of Hairy Cell Leukemia
|
Shah, Harsh
|
|
2016
|
15 |
4 |
p. e235-e239
|
artikel
|
| 14 |
Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials
|
Pei, Xueqing
|
|
2016
|
15 |
4 |
p. e149-e156
|
artikel
|
| 15 |
Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications
|
Hicks, Angel Mier
|
|
2016
|
15 |
4 |
p. 360-368
|
artikel
|
| 16 |
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
|
Pishvaian, Michael
|
|
2016
|
15 |
4 |
p. 345-351
|
artikel
|
| 17 |
Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer
|
Miranda, Vanessa C.
|
|
2016
|
15 |
4 |
p. 321-328.e1
|
artikel
|
| 18 |
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid
|
Yan, Michael
|
|
2016
|
15 |
4 |
p. 369-376.e3
|
artikel
|
| 19 |
Prognostic Significance of Preoperative Serum Carbohydrate Antigen 19-9 in Patients With Stage IV Colorectal Cancer
|
Ozawa, Tsuyoshi
|
|
2016
|
15 |
4 |
p. e157-e163
|
artikel
|
| 20 |
Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice
|
Wilhelm, Martin
|
|
2016
|
15 |
4 |
p. 381-388
|
artikel
|
| 21 |
Screening for Colorectal Cancer: A Systematic Review and Meta-Analysis
|
Fitzpatrick-Lewis, Donna
|
|
2016
|
15 |
4 |
p. 298-313
|
artikel
|
| 22 |
Surgical and Oncologic Outcomes After Major Liver Surgery and Extended Hemihepatectomy for Colorectal Liver Metastases
|
Ubink, Inge
|
|
2016
|
15 |
4 |
p. e193-e198
|
artikel
|
| 23 |
Survival and Prognostic Factors of Colorectal Liver Metastases After Surgical and Nonsurgical Treatment
|
Lemke, Johannes
|
|
2016
|
15 |
4 |
p. e183-e192
|
artikel
|
| 24 |
Table of Contents
|
|
|
2016
|
15 |
4 |
p. A2-A6
|
artikel
|
| 25 |
TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review
|
Zaniboni, Alberto
|
|
2016
|
15 |
4 |
p. 292-297
|
artikel
|
| 26 |
TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study
|
Yoshino, Takayuki
|
|
2016
|
15 |
4 |
p. e205-e211
|
artikel
|
| 27 |
The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials
|
Giuliani, Jacopo
|
|
2016
|
15 |
4 |
p. 277-284
|
artikel
|
| 28 |
The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy
|
Toh, James W.T.
|
|
2016
|
15 |
4 |
p. 285-291
|
artikel
|
| 29 |
Use of Neoadjuvant Chemotherapy Plus Molecular Targeted Therapy in Colorectal Liver Metastases: A Systematic Review and Meta-analysis
|
Sabanathan, Dhanusha
|
|
2016
|
15 |
4 |
p. e141-e147
|
artikel
|
Tijdschrift beschrijving